Company / Capital Expenditures
Altimmune, Inc. Capital Expenditures History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$11.0K
FY2025
5-year range
$11.0K / $12.1M
FY2021-FY2025
Trend
-76.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has declined for 3 consecutive years, from $12M in FY2022 to $11,000 in FY2025.
Based on SEC 10-K filings.
$11,000 in FY2025 with a 5-year CAGR of +55.1%.
Declined from $126,000 to $11,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -90.3%
- 5-Year CAGR
- +55.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Altimmune, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of +55.1%, indicating consistent growth.
- In FY2025, capital expenditures decreased 76.6% year-over-year.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.0K | -76.6% |
| FY2024 | $47.0K | -62.7% |
| FY2023 | $126.0K | -99.0% |
| FY2022 | $12.1M | +5841.0% |
| FY2021 | $204.0K | +16522.4% |
| FY2020 | $1.2K | -99.9% |
| FY2019 | $975.4K | +767.5% |
| FY2018 | $112.4K | -10.0% |
| FY2017 | $125.0K | -66.6% |
| FY2011 | $374.6K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026